Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma
Varun Iyengar(Kettering University), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Monica Masterson(Institute of Cancer Research), Yazeed Sawalha(Cleveland Clinic), Thomas Lucido(Rutgers, The State University of New Jersey), Adrienne Nedved(Mayo Clinic), Joseph F. Parker(Nemours Children's Clinic), Alex F. Herrera(City of Hope), Muhamad Alhaj Moustafa(Jacksonville College), David A. Russler‐Germain(Washington University in St. Louis), Yucai Wang(University of Science and Technology of China), Allison M. Bock(Mayo Clinic), Benjamin Heyman(Fleet Science Center), Heather Rasmussen(University of Washington Medical Center), Michelle Okwali(Memorial Sloan Kettering Cancer Center), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Vincenzo J. Pizzuti(University of Colorado Cancer Center), Michele Stanchina(Sylvester Comprehensive Cancer Center), Ajay Major(University of Colorado Cancer Center), Talal Hilal(WinnMed), Stacy Pak(City Of Hope National Medical Center), Nicole Birrer(University of Utah), Danielle Wallace(Institute of Cancer Research), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Youssef Youssef(The Ohio State University), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lu Chen(City of Hope), Swetha Kambhampati(City Of Hope National Medical Center), Seth Buller(City Of Hope National Medical Center), Alyssa Gibson(University of Chicago), Jomel Meeko Manzano(City Of Hope National Medical Center), Ahmed Bahnasy(TOCA at Banner Health), Patrick Gould(Kettering University), Chaitra Ujjani(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jessica Chicola(Memorial Sloan Kettering Cancer Center), Christine Goth(City Of Hope National Medical Center), Denisse Montana(University of Miami), Peter A. Riedell(University of Chicago), Siang Dim(Dana-Farber Cancer Institute), Hua‐Jay J. Cherng
Cited by 1
Related Papers
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy
|Nature Communications|2020|292
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213